research
Clinical Trials and Therapeutics
Use of antisense oligonucleotide in Progressive supranuclear palsy
Theme Group:
Funding:
Phase 1 clinical trial funded by Novartis
About the project:
Phase 1 first in human clinical trial in patients with progressive supranuclear palsy.
Key iDeAC expertise:
Related projects: